The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation

Am J Hematol. 2019 Feb;94(2):E58-E61. doi: 10.1002/ajh.25361. Epub 2018 Dec 18.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Anticoagulants / adverse effects*
  • Hemorrhage / chemically induced*
  • Heparin, Low-Molecular-Weight / adverse effects
  • Humans
  • Insurance
  • Middle Aged
  • Neoplasms / complications
  • Neoplasms / drug therapy*
  • Recurrence
  • Risk
  • Rivaroxaban / adverse effects
  • Venous Thromboembolism / chemically induced*
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Warfarin
  • Rivaroxaban